Abstract
Despite the introduction of next-generation androgen receptor (AR)–targeted agents for patients with metastatic prostate cancer, resistance — either
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
